ASTRO Multidisciplinary Head and Neck Cancers Symposium 2022

American Society for Radiation Oncology Multidisciplinary Head and Neck Cancers Symposium 2022

Format: 5 videos + 1 pdf, size: 34.1 GB

Course Audience: medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists

Agenda (PDF Format)

Thursday, February 24, 2022 Part 1 (Video MP4 Format)

Thursday, February 24, 2022 Part 2 (Video MP4 Format)

Friday, February 25, 2022 Part 1 (Video MP4 Format)

Friday, February 25, 2022 Part 2 (Video MP4 Format)

Saturday, February 26, 2022 (Video MP4 Format)

 

* Detail:

Wednesday, February 23, 2022

4:00 p.m. – 6:00 p.m.

Registration Open

Thursday, February 24, 2022

7:00 a.m. – 4:30 p.m.	Registration Open
7:00 a.m. – 8:00 a.m.	Continental Breakfast
7:50 a.m. – 8:00 a.m.	Day One Welcome Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana [HNS]
8:00 a.m. – 8:20 a.m.	Patient Perspective: Building a Community of HNL Patients, Coaches and Mentors Speaker: Michael West
8:20 a.m. – 9:50 a.m.	Patient-centric Head and Neck Care  Moderator: Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana [HNS] Comprehensive Rehabilitation of the Head and Neck Patient Heather Starmer, MA, CCC-SLP, BCS-S, Stanford University, Stanford, California [SLP] Oral/Dental Needs in HNC Survivors Joel Epstein, DMD, MSD, Cedars-Sinai, Los Angeles [OMFS] Addressing the Psychological Aspects of Head and Neck Cancer Elizabeth Cash, PhD, University of Louisville, Louisville, Kentucky [Psychologist] The Artistry of Facial Prosthetics Devin Okay, DDS, Mount Sinai Hospital, New York [OMFS] Nutrition in Head and Neck Cancer Patricia Rubio, MBA, MS, University of California, San Diego [Nutritionist] Questions and Answers
9:50 a.m. – 10:35 a.m.	Keynote I: Disparities in Head and Neck Cancer Moderator: Dan Zandberg, MD, University of Pittsburgh Medical Center, Pittsburgh [M] Sharon Spencer, MD, University of Alabama at Birmingham, Birmingham, Alabama [R] Charles Moore, MD, Emory University, Atlanta [HNS]
10:35 a.m. – 11:00 a.m.	Coffee Break
11:00 a.m. – 12:30 p.m.	Escalation Strategies and Novel Approaches in Locally Advanced Head and Neck Cancer Moderator: Julie Bauman, MD, MPH, University of Arizona, Tucson, Arizona [M] Immunotherapy in the Curative Intent Setting Sana Karam, MD, PhD, University of Colorado, Denver [R] The Role of Preop IO in Locally Advanced HNC Ravi Uppaluri, MD, PhD, Brigham and Women’s Hospital, Boston [HNS] Novel Radiosensitizers Heath Skinner, MD, PhD, University of Pittsburgh,  Pittsburgh [R]​ Nasopharynx: Induction vs Adjuvant – Where do we go from here? Dimitrios Colevas, MD, Stanford University, Stanford, California [M] Questions and Answers
12:30 p.m. – 1:30 p.m.	Lunch in the Exhibit Hall Early-career and Trainee Networking Luncheon: Choosing Your Career Path Highlight careers briefly at the beginning and then break out into small groups at the different round tables. Moderator: Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS] Julie Bauman, MD, MPH, University of Arizona, Tucson, Arizona [M] Katherine Hutcheson, PhD, MD Anderson Cancer Center, Houston [Speech Path] Faye Johnson, MD, PhD, MD Anderson Cancer Center, Houston [M] Loren Mell, MD, University of California, San Diego [R] Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS]
1:30 p.m. – 3:00 p.m.	K. Kian Ang, MD, PhD, FASTRO, Commemorative Plenary Session Moderator: Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS] Early Toxicity and Patient Reported Outcomes from a Phase 2 Trial of FDG-PET Response-based De-escalated Definitive Radiotherapy for p16+ Oropharynx Cancer Steven Allen, University of Michigan, Ann Arbor, Michigan Non-inferiority Margin and Nodal Analysis of De-escalated Adjuvant Radiation Therapy (DART) for HPV-related Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Preplanned Pooled Analysis of MC1273 & MC1675 Daniel Ma, Mayo Clinic, Rochester, Minnesota Detection of Occult Recurrence Using Circulating HPV Tumor DNA among Patients Treated for HPV-driven Oropharyngeal Squamous Cell Carcinoma Glenn Hanna, Dana-Farber Cancer Institute, Harvard Medical School, Boston Kinetics of Circulating Human Papillomavirus (cHPV) DNA in Plasma and Oral Gargles from Patients with HPV-positive Oropharyngeal Cancer (OPC) Treated with Definitive Radiation Therapy Michelle Echevarria, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida A Clinically Translatable, Extensively Validated Immune-based Classification of Human Papillomavirus-associated Head and Neck Cancer with Implications for Treatment Deintensification and Immunotherapy Peter Zeng, Western University, London, Ontario, Canada Predicted Th2 Infiltrate is Associated with Outcome in HPV(-) Head and Neck Cancer Mohamed Abdelhakiem, UPMC Hillman Cancer Center, Pittsburgh Loss of HPV 16- E2 Predicts Disease Free Survival and Promotes Platinum Resistance in Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma Molly Heft-Neal, University of Michigan, Ann Arbor, Michigan Neoadjuvant Immunoradiotherapy in a Tobacco-Signature Preclinical Oral Squamous Cell Carcinoma Model Robert Saddawi-Konefka, University of California, San Diego HPV E5 Mediates Resistance to PD-1 Checkpoint Blockade via Inhibition of MHC and IFN Pathway Andrew Sharabi, University of California, San Diego
3:00 p.m. – 3:30 p.m.	Coffee Break
3:30 p.m. – 4:30 p.m.	Case Study and Debate: Curative Intent in Elderly and Frail Moderator: Zain Husain, MD, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada [R] Susan McCammon, MD, University of Alabama, Birmingham, Birmingham, Alabama [HNS] Loren Mell, MD, University of California, San Diego [R] Paul Loren Swiecicki, MD, University of Michigan, Ann Arbor, Michigan [M] Questions and Answers
4:30 p.m. – 5:30 p.m.	Research Feature and Networking Reception

Friday, February 25, 2022

7:00 a.m. – 5:30 p.m.	Registration Open
7:00 a.m. – 8:00 a.m.	Continental Breakfast
7:55 a.m. – 8:00 a.m.	Day Two Welcome Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R]
8:00 a.m. – 8:20 a.m.	Patient Perspective Speaker: Andy Pluemer
8:20 a.m. – 9:40 a.m.	HOT TOPIC: Early Oral Cavity Moderator: Mike Moore, MD, Indiana University of Medicine, Indianapolis [HNS] Tumor Board Intraoperative Margin Assessment Mark Varvares, MD, FACS, Massachusetts General Hospital, Boston [HNS] Pathologist’s Perspective Margaret Brandwein-Weber, MD, Mount Sinai, New York [Pathologist] Sentinel Node and Neck Dissection Stephen Lai, MD, PhD, FACS, MD Anderson Cancer Center, Houston [HNS] New Frontiers in Sx: Fluorescence Guided Sx Eben Rosenthal, MD, Vanderbilt University Medical Center, Nashville [HNS] Surgical Reconstruction Kelly Malloy, MD, University of Michigan, Ann Arbor, Michigan [HNS]
9:40 a.m. – 10:25 a.m.	Keynote II: Towards Personalization of HPV Related Oropharyngeal Carcinoma Moderator: Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R] Speaker: Nancy Lee, MD, FASTRO, Memorial Sloan Kettering Cancer Center, New York [R]
10:25 a.m. – 10:50 a.m.	Coffee Break
10:50 a.m. – 12:20 p.m.	Plenary II Moderator: Alexander Pearson, MD, PhD, University of Chicago, Chicago [M] An Artificial Intelligence Ultrasound Platform for Screening and Staging of Thyroid Cancer Annie Chan, Massachusetts General Hospital, Harvard Medical School, Boston Development of a Deep Learning-based Auto-segmentation of Organs at Risk for Head and Neck Radiotherapy Planning Jihye Koo, University of South Florida, Tampa, Florida Safety and Efficacy of RP1 + Nivolumab in Patients with Non-melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-cohort Clinical Trial Jiaxin Niu, Banner MD Anderson Cancer Center, Houston A Novel Intratumoral Microdosing Approach for Simultaneously Evaluating Multiple Drugs and Combinations in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) Harrison Cash, University of Washington Medical Center, Seattle Efficacy and Safety of Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma: Results from a Phase II Cohort May Cho, MD, University of California, Irvine, CA Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Carcinoma: Results from the Phase II LT-SABR Study David Sher, University of Texas Southwestern Medical Center, Dallas Standard but Not Equal: Disparities in Advanced Radiotherapy Techniques for Head and Neck Cancer in the United States Neal McCall, Winship Cancer Institute of Emory University, Atlanta Focal Adhesion Kinase Drives Resistance to Therapy in HPV-Negative Head and Neck Squamous Cell Carcinoma in a P53-Dependent Manner Phillip Pifer, UPMC Hillman Cancer Center, Pittsburgh
12:20 p.m. – 1:20 p.m.	Lunch in the Exhibit Hall Early-career and Trainee Networking Luncheon: Launching Your Successful Career How to Get Your Paper Published Renata Ferrarotto, MD, MD Anderson Cancer Center, Houston, Texas [M] Finding Personal/Professional Balance Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana [HNS] Seeking Out and Maintaining Mentoring Relationships Zain Husain, MD, Sunnybrook Health Sciences Centre, Ontario, Canada [Dermatologist]
1:20 p.m. – 2:35 p.m.	Panel: Thyroid Moderator: Sue Yom, MD, PhD, FASTRO, University of California, San Francisco [R] Mutational Landscape of Thyroid Cancers Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta [M] Low Risk Thyroid Cancer/RAI Jennifer Sipos, MD, The Ohio State University, Columbus, Ohio [Endocrinologist] Therapies for High Risk and Anaplastic Thyroid Cancer Saad Khan, MD, Stanford University, Stanford, California [M] Multimodality Therapy for Aggressive Differentiated Thyroid Cancers Mark Zafereo, MD, FACS, MD Anderson Cancer Center, Houston [HNS]
2:35 p.m. – 3:00 p.m.	Coffee Break
3:00 p.m. – 4:30 p.m.	HOT Topic: Options in Advanced Skin Squamous Cell Carcinoma Moderator: Robert Ferris, MD, PhD, University of Pittsburgh [R] Controversies in Surgical Management Cecelia Schmalbach, MD, MSc, FACS, Temple Health, Philadelphia [HNS] Role of Radiation ​Shlomo Koyfman, MD, Cleveland Clinic, Cleveland [R] Systemic Therapy Jessica Geiger, MD, Cleveland Clinic Cancer Center, Cleveland [M Immunotherapy in Special Populations Anne Chang, MD, Stanford University, Stanford, California [Dermatologist] Questions and Answers
4:30 p.m. – 5:30 p.m.	Development of Survivorship Programs Moderator: Jon Irish, MD, MSc, FRCSC, FACS, University of Toronto, Toronto, Ontario,Canada [HNS] Developing Care Pathways Liza Blumenfeld, MA, CCC-SLP, BCS-S, University of California, San Diego [SLP] Practice and Research Marci Lee Nilsen, PhD, RN, University of Pittsburgh, Pittsburgh [RN] Financial Toxicity Jonas de Souza, MD, MBA, HCA Healthcare, Nashville [M] Questions and Answers

Saturday, February 26, 2022

7:00 a.m. – 12:15 p.m.	Registration Open
7:00 a.m. – 8:00 a.m.	Continental Breakfast
7:55 a.m. – 8:00 a.m.	Day Three Welcome Faye Johnson, MD, PhD, MD Anderson Cancer Center, Houston [M]
8:00 a.m. – 8:20 a.m.	Patient Perspective David Burkett
8:20 a.m. – 9:45 a.m.	De-escalation for HPV Moderator: Katherine Hutcheson, PhD, MD Anderson Cancer Center, Houston, [SLP] Introduction Katherine Hutcheson, PhD, MD Anderson Cancer Center, Houston [SLP] Surgical Considerations Umamaheswar Duvvuri, MD, PhD, University of Pittsburgh, Pittsburgh [HNS] Radiation Considerations Bhisham Chera, MD, UNC School of Medicine, Chapel Hill, North Carolina [R] Systemic Considerations Neil Hayes, MD, The University of Tennessee Health Science Center, Memphis, Tennessee [M] Questions and Answers
9:45 a.m. – 10:30 a.m.	Salivary Cancers Moderator: Assuntina Gesualda Sacco, MD, University of California, San Diego, Moores Cancer Center, La Jolla, California [M] Current Approaches to Managing Salivary Cancer Kiran Kakarala, MD, University of Kansas Medical Center, Kansas City, Kansas [HNS] Novel Systemic Treatment for Recurrent or Metastatic Salivary Cancers Renata Ferrarotto, MD, MD Anderson Cancer Center, Houston [M] Questions and Answers
10:30 a.m. – 10:45 a.m.	Coffee Break
10:45 a.m. – 12:15 p.m.	Recurrent and Metastatic Head and Neck Cancer Moderator: Farzan Siddiqui, MD, PhD, Henry Ford Cancer Institute, Detroit [R] Re-irradiation for Recurrent and Second Primary Head and Neck Cancers Neal Dunlap, MD, University of Louisville, Louisville, Kentucky [R] ​ Surgical Salvage with Reconstruction Urjeet Patel, MD, Northwestern Hospital, Chicago [HNS] Novel Targeted and Immunotherapies Christine Chung, MD, Moffitt Cancer Center, Tampa, Florida [M] Case Discussions